GlobeNewsWire
15 Aug 2026, 18:28 UTC · 8h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
The FDA stated that the benefit-risk assessment for deramiocel appears unfavorable due to a lack of evidence of effectiveness. — A negative effectiveness assessment from the FDA is a critical blow to the likelihood of drug approval, which is the primary value driver for biotech companies.
-1.00The FDA disagreed with changes Capricor made to its statistical analysis plan, stating they were not scientifically justified and reduced accuracy. — Regulatory disagreement over data integrity and analysis methods severely undermines the credibility of clinical trial results.
-0.80A securities fraud class action lawsuit has been filed against Capricor Therapeutics alleging misleading statements regarding the Deramiocel BLA process. — Litigation creates additional financial liability and management distraction, though it is secondary to the underlying regulatory failure.
-0.50Continue reading
6 related stories
Search tags
Capricor stock fell 64% following the release of FDA briefing documents on July 27, 2026. — This confirms a massive loss of market capitalization and indicates that a significant portion of the negative news has already been priced in.
-0.30Which stocks this story touches
The company is facing a securities fraud class action lawsuit and its stock dropped 64% following negative FDA feedback on its BLA.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
MarketBeat
1h ago
